作者: Bph773 時間: 2025-3-21 21:49 作者: kyphoplasty 時間: 2025-3-22 04:03 作者: indifferent 時間: 2025-3-22 08:29
https://doi.org/10.1007/978-94-009-4468-8llow greater power of the tests. Some of these procedures are quite advanced and pioneering, but are mostly developed for fixed-sample trials without interim looks of the accumulating data of the trial. Extensions of these approaches to group sequential trials which permit interim looks for stopping作者: 胰島素 時間: 2025-3-22 10:57
M. Poetke,C. Philipp,H. P. Berlienons other than those with two chronic studies in rats and mice were either not discussed or barely mentioned in the 2001 draft guidance document. They are submissions including one chronic study in rats and one six-month study in transgenic mice and submissions including only one chronic study in ei作者: Ascribe 時間: 2025-3-22 14:18
H.-P. Berlien,P. P. Schmittenbecherat six-month intervals until the end of the study..Data were collected on 31 patients. Because a large group difference became apparent after six months of treatment, the group randomization code was broken. It was found that 16 patients had been randomized to alendronate and 15 to placebo..: Due to作者: transplantation 時間: 2025-3-22 19:49 作者: 惡名聲 時間: 2025-3-23 00:05
8.1 Crystal growth and wafer technology,ional examples in the broader biopharmaceutical operational and scientific context are provided. The tepee plot creates an easy to interpret visual of complex data. The extent and location of the colors tell us the extent to which an input of interest is distributed over column attributes and row le作者: progestogen 時間: 2025-3-23 04:11
12.1 Standard characterization methods,he randomly permuted data using our heuristic as well as other alternative methods such as those in Sakai et al. (.). RESULTS: Results validate our methods. The method is demonstrated through a visual representation of changes in cancer states for two induction therapies in a cancer trial. A further作者: 漂亮 時間: 2025-3-23 09:10 作者: Increment 時間: 2025-3-23 10:05 作者: aspersion 時間: 2025-3-23 15:50
Recycling of Significance Levels in Testing Multiple Hypotheses of Confirmatory Clinical Trials,with different weights by importance or power considerations. This structuring also allows using methods that allow recycling of the significance level of a successfully rejected hypothesis within a set or family to other hypotheses in the same set or family or to a hypothesis in the next family. A 作者: 在駕駛 時間: 2025-3-23 20:54
Statistical Testing of Single and Multiple Endpoint Hypotheses in Group Sequential Clinical Trials,llow greater power of the tests. Some of these procedures are quite advanced and pioneering, but are mostly developed for fixed-sample trials without interim looks of the accumulating data of the trial. Extensions of these approaches to group sequential trials which permit interim looks for stopping作者: oxidant 時間: 2025-3-23 22:57 作者: Commodious 時間: 2025-3-24 04:24 作者: upstart 時間: 2025-3-24 09:19
Validation, Multivariate Modeling, and the Construction of Heat-Map Prediction Matrices for Survivaation of this analysis route in the context of missing data. The construction of the heat-map prediction matrix will be demonstrated for the categorical endpoint of deaths within 180?days and 3-year survival post-enrollment for patients with newly diagnosed multiple myeloma. Relevant R and SAS codes作者: 取之不竭 時間: 2025-3-24 14:30
Tepee Plots, Graphics for Structured Tabular Data, with Biopharmaceutical Examples,ional examples in the broader biopharmaceutical operational and scientific context are provided. The tepee plot creates an easy to interpret visual of complex data. The extent and location of the colors tell us the extent to which an input of interest is distributed over column attributes and row le作者: painkillers 時間: 2025-3-24 17:01
Some Methods for Longitudinal and Cross-Sectional Visualization with Further Applications in the Cohe randomly permuted data using our heuristic as well as other alternative methods such as those in Sakai et al. (.). RESULTS: Results validate our methods. The method is demonstrated through a visual representation of changes in cancer states for two induction therapies in a cancer trial. A further作者: FOIL 時間: 2025-3-24 21:31 作者: 瑪瑙 時間: 2025-3-24 23:25
2199-0980 cs covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine – Design Consideratio978-981-13-4006-2978-981-10-7820-0Series ISSN 2199-0980 Series E-ISSN 2199-0999 作者: 抵押貸款 時間: 2025-3-25 03:58
Biopharmaceutical Applied Statistics Symposium978-981-10-7820-0Series ISSN 2199-0980 Series E-ISSN 2199-0999 作者: troponins 時間: 2025-3-25 08:37 作者: 閹割 時間: 2025-3-25 14:46 作者: 反復無常 時間: 2025-3-25 17:26
https://doi.org/10.1007/978-981-10-7820-0Optimal Individualized Treatment Rules; Mixture Normal Distribution; Personalized Medicine; Phase III O作者: GUILE 時間: 2025-3-25 21:53 作者: Cognizance 時間: 2025-3-26 01:02 作者: 驚奇 時間: 2025-3-26 08:00 作者: 圖表證明 時間: 2025-3-26 11:41
Conduction Heating of Solid Surfaces,o therapeutic agents depends to a critical degree on how “synergy” is defined and how the data are analyzed. To illustrate these points, a hypothetical example based on an actual case is discussed. In the example, a common set of clinical trials was analyzed by two different organizations with two d作者: Scleroderma 時間: 2025-3-26 15:05 作者: DIS 時間: 2025-3-26 17:00 作者: 松馳 時間: 2025-3-27 00:43 作者: VOC 時間: 2025-3-27 03:41
H.-P. Berlien,P. P. Schmittenbechers in decreases in glucosylceramide storage in the liver and spleen, but signs and symptoms of osteopenia have proven refractory to enzyme therapy..The purpose of this investigation was to determine whether the osteopenia of GD can be corrected by bone anti-resorptive therapy in patients who are rece作者: 割讓 時間: 2025-3-27 07:38
The Use of Lasers in Pediatric Neurosurgery,een developed for continuous outcomes. When the outcome of interest is non-continuous (e.g., binary, count, or zero-inflated count), mediation approaches relying on linear models may not be appropriate. This chapter introduces the framework and definition of direct and indirect (mediation)treatment 作者: 過于平凡 時間: 2025-3-27 13:21 作者: Bph773 時間: 2025-3-27 16:34
12.2 Reliability and life time, instead of a crossover design in a bioequivalence trial of several formulations. This trial also incorporated blinded sample size re-estimation—before there was a literature on the subject. Two other applications, one of a fixed combination drug for treating allergic rhinitis and the other of a dos作者: vitreous-humor 時間: 2025-3-27 20:19
12.2 Reliability and life time,alyses in the context of the original scientific questions that we intend to answer in a clinical trial. Missing data, a ubiquitous problem in clinical trials, require additional assumptions and choices on how to collect and analyze data that can have an unexpected impact on the interpretation of th作者: 安定 時間: 2025-3-28 00:52 作者: GRAVE 時間: 2025-3-28 02:44
8.1 Crystal growth and wafer technology,) will be demonstrated. Such a graphic can be applied to any tabular data in rows and columns where an ordering exists among the rows. The plot is introduced with examples in organizational structure in the biopharmaceutical context followed by a theoretical description of the method of constructing作者: 起草 時間: 2025-3-28 09:54 作者: 半身雕像 時間: 2025-3-28 13:40
Karl E. Peace,Ding-Geng Chen,Sandeep MenonDiscusses updated design and analysis methods for biopharmaceutical clinical trials.Includes chapters written by internationally respected authors from academia, government and industry who possess su作者: 樹木中 時間: 2025-3-28 16:48
ICSA Book Series in Statisticshttp://image.papertrans.cn/b/image/188313.jpg作者: strain 時間: 2025-3-28 20:55 作者: 煩擾 時間: 2025-3-28 23:04 作者: backdrop 時間: 2025-3-29 05:46 作者: 粉筆 時間: 2025-3-29 10:20 作者: 火車車輪 時間: 2025-3-29 15:06 作者: construct 時間: 2025-3-29 15:50
Targeted Learning of Optimal Individualized Treatment Rules Under Cost Constraints,We consider a general resource-allocation problem, namely, to maximize a mean outcome given a cost constraint, through the choice of a treatment rule that is a function of an arbitrary fixed subset of an individual’s covariates.作者: Nonthreatening 時間: 2025-3-29 21:05 作者: Cantankerous 時間: 2025-3-30 03:44
Uncovering Fraud, Misconduct, and Other Data Quality Issues in Clinical Trials,This chapter summarizes statistical and graphical approaches to evaluate data quality in clinical trials. Distinguishing between fraud, misconduct, and carelessness for data aberrations is discussed. Several methods are illustrated using a clinical trial of patients who experienced an aneurysmal subarachnoid hemorrhage.作者: Armada 時間: 2025-3-30 05:15 作者: AVOID 時間: 2025-3-30 09:23 作者: configuration 時間: 2025-3-30 14:55
The Use of Lasers in Pediatric Neurosurgery,re discussed under a variety of settings where post-baseline confounders and unmeasured confounders may be a concern, and under a series of assumptions with and without sequential ignorability. Methods are illustrated with application to a randomized dental caries prevention trial.作者: Indebted 時間: 2025-3-30 18:13 作者: 彎曲道理 時間: 2025-3-30 22:08 作者: Fierce 時間: 2025-3-31 01:10
2199-0980 uthors from academia, government and industry who possess suThis BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments – particularly biopharmaceutical clinical trials. ?The papers were selected f作者: Hay-Fever 時間: 2025-3-31 06:01
Optical energy transfer in insulators,tion, novel biomarker-based clinical trial designs have been proposed and have proven beneficial to many clinical programs. In this chapter, we discuss the omics technologies and statistical issues that are related to biomarker discovery. We also provide an overview of current development of biomarker-enabled clinical trial designs.作者: 委托 時間: 2025-3-31 09:51 作者: Ornament 時間: 2025-3-31 16:40 作者: 偽書 時間: 2025-3-31 20:20 作者: 負擔 時間: 2025-4-1 01:18 作者: cathartic 時間: 2025-4-1 02:38
Interesting Applications from Three Decades of Biostatistical Consulting,d later dose discrimination, as well as illustrating the need to carefully define the trial objective. The last example provides an overview of assessing whether evidence exists from two Phase II trials of angina to support conducting a Phase III trial at either a b.i.d. or t.i.d. drug.作者: diabetes 時間: 2025-4-1 09:01
Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trih-throughput omics technologies has enabled scientists to discover new biomarkers with low cost. Leveraging available technology and biomarker information, novel biomarker-based clinical trial designs have been proposed and have proven beneficial to many clinical programs. In this chapter, we discus作者: seroma 時間: 2025-4-1 10:43
Phase 3 Oncology Trials of Personalized Medicines with Adaptive Subpopulation Selection,ever, there is great uncertainty about drug activity in a subpopulation when designing a confirmatory trial in practice and it is logical to take a two-stage adaptive approach. The first stage de-selects (or prunes) non-performing subpopulations at an interim analysis, and the second stage pools the作者: 刺激 時間: 2025-4-1 17:19
,Synergy or Additivity—The Importance of Defining the Primary Endpoint and the Approach to Its Statio therapeutic agents depends to a critical degree on how “synergy” is defined and how the data are analyzed. To illustrate these points, a hypothetical example based on an actual case is discussed. In the example, a common set of clinical trials was analyzed by two different organizations with two d作者: 良心 時間: 2025-4-1 19:27
Recycling of Significance Levels in Testing Multiple Hypotheses of Confirmatory Clinical Trials, types and sometimes into other lower types. The primary hypotheses enjoy a special status; if the trial wins for one or more primary hypotheses, then one can characterize clinically relevant benefits of the study treatment. This framework of classifying hypotheses based on their importance into pri
